Neuromodulatory therapies in female pelvic medicine and reconstructive surgery: Biological agents

BJU International

Volumn 98, Issue SUPPL. 1, 2006, Pages 50-60

  Schulte Baukloh, Heinrich ^a   Knispel, Helmut H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Botox; Botulinum toxin; Capsaicin; Detrusor overactivity; Overactive bladder; Resiniferatoxin; Vanilloids

Indexed keywords

BOTULINUM TOXIN A; CAPSAICIN; RESINIFERATOXIN;

CLINICAL FEATURE; CLINICAL TRIAL; DETRUSOR MUSCLE; DRUG MECHANISM; HUMAN; MEDICAL LITERATURE; MUSCLE CONTRACTION; NEUROMODULATION; PELVIS SURGERY; PLASTIC SURGERY; PRIORITY JOURNAL; REVIEW; URGE INCONTINENCE;

BOTULINUM TOXINS; CAPSAICIN; DITERPENES; FEMALE; HUMANS; NEUROTOXINS; PELVIC FLOOR; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, NEUROGENIC; URINARY INCONTINENCE;

EID: 33746725412     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06311.x     Document Type: Review

References (82)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78
2. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6
3. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36
4. Kelleher CJ, Kreder KJ, Pleil AM, Burgess SM, Reese PR. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002; 8 (Suppl. 19): S616-30
5. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care 2000; 11 (Suppl. 11): S580-90
6. Szallasi A, Fowler CJ. After a decade of intravesical vanilloid therapy: still more questions than answers. Lancet Neurol 2002; 1: 167-72
7. Cruz F. Mechanisms involved in new therapies for overactive bladder. Urology 2004; 63 (Suppl. 3): 65-73
8. Craft RM, Cohen SM, Porreca F. Long-lasting desensitization of bladder afferents following intravesical resiniferatoxin and capsaicin in the rat. Pain 1995; 61: 317-23
9. Yiangou Y, Facer P, Ford A et al. Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder. BJU Int 2001; 87: 774-9
10. Birder LA, Kanai AJ, de Groat WC et al. Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc Natl Acad Sci USA 2001; 98: 13396-401
11. Apostolidis A, Brady CM, Yiangou Y, Davis J, Fowler CJ, Anand P. Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin. Urology 2005; 65: 400-5
12. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389: 816-24
13. Caterina MJ, Leffler A, Malmberg AB et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000; 288: 306-13
14. Blok BF. Central pathways controlling micturition and urinary continence. Urology 2002; 59 (Suppl. 5): 13-7
15. De Ridder D, Baert L. Vanilloids and the overactive bladder. BJU Int 2000; 86: 172-80
16. Fowler CJ. Bladder afferents and their role in the overactive bladder. Urology 2002; 59 (Suppl. 5): 37-42
17. Birder LA, Nakamura Y, Kiss S et al. Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosci 2002; 5: 856-60
18. Brady CM, Apostolidis AN, Harper M et al. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int 2004; 93: 770-6
19. Maggi CA, Santicioli P, Borsini F, Giuliani S, Meli A. The role of the capsaicin-sensitive innervation of the rat urinary bladder in the activation of micturition reflex. Naunyn Schmiedebergs Arch Pharmacol 1986; 332: 276-83
20. Maggi CA, Barbanti G, Santicioli P et al. Cystometric evidence that capsaicin-sensitive nerves modulate the afferent branch of micturition reflex in humans. J Urol 1989; 142: 150-4
21. Fowler CJ. Intravesical treatment of overactive bladder. Urology 2000; 55 (Suppl. 5A): 60-4
22. Pannek J, Grigoleit U, Wormland R, Goepel M. [Intravesical therapy for overactive bladder]. Urologe A 2006; 45: 167-8
23. Fowler CJ, Beck RO, Gerrard S, Betts CD, Fowler CG. Intravesical capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry 1994; 57: 169-73
24. Geirsson G, Fall M, Sullivan L. Clinical and urodynamic effects of intravesical capsaicin treatment in patients with chronic traumatic spinal detrusor hyperreflexia. J Urol 1995; 154: 1825-9
25. Cruz F, Guimaraes M, Silva C, Rio ME, Coimbra A, Reis M. Desensitization of bladder sensory fibers by intravesical capsaicin has long lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction. J Urol 1997; 157: 585-9
26. De Ridder D, Chandiramani V, Dasgupta P, Van Poppel H, Baert L, Fowler CJ. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term followup. J Urol 1997; 158: 2087-92
27. de Seze M, Wiart L, Joseph PA, Dosque JP, Mazaux JM, Barat M. Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn 1998; 17: 513-23
28. Wiart L, Joseph PA, Petit H et al. The effects of capsaicin on the neurogenic hyperreflexic detrusor. A double blind placebo controlled study in patients with spinal cord disease. Preliminary results. Spinal Cord 1998; 36: 95-9
29. Giannantoni A, Di Stasi SM, Stephen RL et al. Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. J Urol 2002; 167: 1710-4
30. Silva C, Ribeiro MJ, Cruz F. The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J Urol 2002; 168: 575-9
31. Kim JH, Rivas DA, Shenot PJ et al. Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med 2003; 26: 358-63
32. Kuo HC. Effectiveness of intravesical resiniferatoxin in treating detrusor hyperreflexia and external sphincter dyssynergia in patients with chronic spinal cord lesions. BJU Int 2003; 92: 597-601
33. Kuo HC. Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions. J Urol 2003; 170: 835-9
34. de Seze M, Wiart L, de Seze MP et al. Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a double-blind, randomized, controlled study. J Urol 2004; 171: 251-5
35. Kuo HC. Multiple intravesical instillation of low-dose resiniferatoxin is effective in the treatment of detrusor overactivity refractory to anticholinergics. BJU Int 2005; 95: 1023-7
36. Silva C, Silva J, Ribeiro MJ, Avelino A, Cruz F. Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial. Eur Urol 2005; 48: 650-5
37. Yokoyama T, Nozaki K, Fujita O, Nose H, Inoue M, Kumon H. Role of C afferent fibers and monitoring of intravesical resiniferatoxin therapy for patients with idiopathic detrusor overactivity. J Urol 2004; 172: 596-600
38. Silva C, Silva J, Castro H et al. The effect of bladder sensory input modulation on urgency: data from a placebo- controlled trial with intravesical resiniferatoxin. Eur Urol 2006; 5: 222, Abstract 797
39. Payne CK, Mosbaugh PG, Forrest JB et al. Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J Urol 2005; 173: 1590-4
40. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988; 139: 919-22
41. Stöhrer M, Schurch B, Kramer G et al. Botulinum A-toxin in the treatment of detrusor hyperreflexia in spinal cord injured patients: a new alternative to medical and surgical procedures? Neurourol Urodyn 1999; 18: 401-2
42. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164: 692-7
43. Kerner J. Das Fettgift oder die Fettsäure und ihre Wirkungen auf den thierischen Organismus, ein Beytrag zur Untersuchung des in verdorbenen Würsten giftig wirkenden Stoffes. Stuttgart, Tübingen: Cotta, 1822
44. Van Ermengem E. Über einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Ztsch Hyg Infekt 1897; 26: 1-56
45. Naumann M, Toyka KV, Moore P. History and current applications of botulinum toxin - from poison to remedy. In Handbook of Botulinum Toxin Treatment. Oxford: Blackwell Science, 2003: 3-8
46. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 1981; 79: 734-70
47. Jankovic J, Brin MF. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve Suppl 1997; 6: S129-45
48. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997; 6: S146-68
49. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci 1999; 96: 3200-5
50. Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin has antinociceptive effects in treating interstitial cystitis. Urology 2004; 64: 871-5
51. Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 2006; 49: 704-9
52. Kuo HC. Preliminary results of suburothelial injection of botulinum A toxin in the treatment of chronic interstitial cystitis. Urol Int 2005; 75: 170-4
53. Schulte-Baukloh H, Weiss C, Stolze T, Sturzebecher B, Knispel HH. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 2005; 66: 82-7
54. Apostolidis A, Popat R, Yiangou Y et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174: 977-83
55. Khera M, Somogyi GT, Kiss S, Boone TB, Smith CP. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 2004; 45: 987-93
56. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 2004; 172: 1529-32
57. Haferkamp A, Schurch B, Reitz A et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 2004; 46: 784-91
58. Comperat E, Reitz A, Delcourt A et al. Histological features in the urinary bladder wall affected by neurogenic overactivity, a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 2006; 5: 80, A229
59. De Laet K, Wyndaele JJ. Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord 2005; 43: 397-9
60. Reitz A, Stohrer M, Kramer G et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45: 510-5
61. Schurch B, de Seze M, Denys P et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005; 174: 196-200
62. Game X, Bentaleb Y, Thiry-Escudie I et al. Detrusor injections of botulinum toxin A in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 2006; 5: 229, A1107
63. Grosse J, Kramer G, Stoehrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005; 47: 653-9
64. Schulte-Baukloh H, Knispel HH, Stolze T et al. Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 2005; 66: 865-70
65. Schulte-Baukloh H, Schobert J, Weiss C et al. Botulinum toxin type A as an alternative in the treatment of hyperactive bladder dysfunction: what do patients think? Urologe A 2003; 1: 42, A4.8
66. Chancellor M, O'Leary M, Erickson J et al. Successful use of bladder botulinum toxin injection to treat refractory overactive bladder. J Urol 2003; 169: 351, Abstract
67. Rapp DE, Lucioni A, Katz EE, O'Connor RC, Gerber GS, Bales GT. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 2004; 63: 1071-5
68. Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004; 63: 868-72
69. Flynn MK, Webster GD, Amundsen CL. The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol 2004; 172: 2316-20
70. Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005; 24: 231-6
71. Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 2005; 66: 94-8
72. Schulte-Baukloh H, Weiss C, Stolze T et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 2005; 48: 984-90
73. Smith CP, Nishiguchi J, O'Leary M, Yoshimura N, Chancellor MB. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 2005; 65: 37-41
74. Werner M, Schmid DM, Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 2005; 192: 1735-40
75. Sahai A, Khan S, Dasgupta P. Botulinum toxin A is safe and effective in the treatment of patients with overactive bladder and idiopathic detrusor overactivity: results from a randomised, double-blind, placebo-controlled trial. Eur Urol 2006; 5: 118, A381
76. Digesu GA, Hutchings A, Salvatore S, Selvaggi L, Milani R, Khullar V. Pressure flow study: a useful diagnostic test of female lower urinary tract symptoms. Neurourol Urodyn 2004; 23: 104-8
77. Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 2004; 172: 240-3
78. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005; 174: 984-9
79. Dykstra D, Enriquez A, Valley M. Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14: 424-6
80. Pistolesi D, Selli C, Rossi B, Stampacchia G. Botulinum toxin type B for type A resistant bladder spasticity. J Urol 2004; 171: 802-3
81. Reitz A, Schurch B. Botulinum toxin type B injection for the management of type A resistant neurogenic detrusor overactivity. J Urol 2004; 171: 804-5
82. Ghei M, Maraj BH, Miller R et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 2005; 174: 1873-7